---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261797"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:53:44.189209+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports Q3 net loss $80.9M; cash $390.9M; PEAK, APEX readouts in Nov/Dec 2025

## Summary
- Cash, cash equivalents and marketable securities at $390.9M; pro forma cash $430M expected to fund into 2027.
- Net loss of $80.9M (Q3 2025) vs $70.6M (Q3 2024); R&D expenses $69.0M.
- Phase 3 PEAK (GIST) top-line results expected Nov 2025; APEX (AdvSM) in Dec 2025.
- NDA filing for NonAdvSM on track for year-end 2025; Breakthrough Therapy Designation granted for bezuclastinib.
- Raised $215.8M net from public offering and $39M from ATM since July 2025.

## SEC filing metadata
- accession: 0001193125-25-261797
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/0001193125-25-261797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261797
- JSON: https://secwatch.observer/filing/0001193125-25-261797.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.